On October 30, DUALITYBIO-B fell 5.03% in Regular Trading, trading at HK$104.0, with turnover of HK$122 million.
The most recent disclosed catalyst points to continued market digestion of the company’s DB-1303 global phase 3 data, even after directors and senior management voluntarily committed to a six-month lock-up effective October 29.
Company disclosures show the lock-up runs through April 28 and covers shares directly or indirectly beneficially owned by directors and senior management, including shares obtained from option exercises. That followed recent shareholder-support actions, including cumulative buybacks of 794,200 shares for about HK$125 million and the chairman’s plan to further increase holdings by up to US$5 million. However, the latest market focus remains on DB-1303: while the trial met its primary endpoint, progression-free survival improvement was described as statistically significant but modest, and interstitial lung disease incidence was higher than in prior studies, with some severe and fatal cases reported.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments